Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on addressing drug resistance in cancer, announced that President and Chief Scientific Officer Neil Bhowmick is presenting interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. The presentation details a statistically significant improvement in median progression-free survival (PFS) for patients receiving ENV-105 in combination with apalutamide compared with apalutamide alone in metastatic castration-resistant prostate cancer (mCRPC).
According to the interim analysis of the Phase 2 trial, patients treated with the combination achieved a median PFS of 17.7 months versus two months for those receiving apalutamide alone (P=0.0008). The result is important because it suggests that targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy, may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies. For patients with mCRPC, a condition that inevitably develops resistance to standard androgen receptor pathway inhibitors, the findings point to a potential new approach to extending the benefit of existing treatments.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer and in the Phase 2 trial in combination with apalutamide for mCRPC. Based on the interim data, the trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group. Previous preclinical research has also demonstrated the potential of ENV-105 to enhance radiation sensitivity in prostate cancer models, further supporting the company's hypothesis that targeting CD105 may address treatment resistance across multiple cancer types.
Bhowmick said the findings support the company's hypothesis that targeting CD105 may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies. The announcement is significant for the oncology community because drug resistance remains a major obstacle to durable responses in prostate cancer and other malignancies. If the Phase 2 results are confirmed in the expanded first-line setting, ENV-105 could offer a new strategy for patients whose tumors have become resistant to standard therapies. For investors, the statistically significant PFS benefit provides a key clinical milestone for Kairos Pharma's lead candidate. The full press release is available at https://ibn.fm/PIrky, and the latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA.
The announcement was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform's reach includes editorial syndication to 5,000+ outlets and press release enhancement designed to ensure maximum impact. Terms of use and disclaimers applicable to all content provided by TinyGems are available at https://www.TinyGems.com/Disclaimer.
